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Abstract 
Purpose: Contemporary trauma resuscitation prioritizes control of bleeding and uses major haemorrhage protocols 
(MHPs) to prevent and treat coagulopathy. We aimed to determine whether augmenting MHPs with Viscoelastic Hae‑
mostatic Assays (VHA) would improve outcomes compared to Conventional Coagulation Tests (CCTs).
Methods: This was a multi‑centre, randomized controlled trial comparing outcomes in trauma patients who received 
empiric MHPs, augmented by either VHA or CCT‑guided interventions. Primary outcome was the proportion of sub‑
jects who, at 24 h after injury, were alive and free of massive transfusion (10 or more red cell transfusions). Secondary 
outcomes included 28‑day mortality. Pre‑specified subgroups included patients with severe traumatic brain injury 
(TBI).
Results: Of 396 patients in the intention to treat analysis, 201 were allocated to VHA and 195 to CCT‑guided therapy. 
At 24 h, there was no difference in the proportion of patients who were alive and free of massive transfusion (VHA: 
67%, CCT: 64%, OR 1.15, 95% CI 0.76–1.73). 28‑day mortality was not different overall (VHA: 25%, CCT: 28%, OR 0.84, 
95% CI 0.54–1.31), nor were there differences in other secondary outcomes or serious adverse events. In pre‑specified 
subgroups, there were no differences in primary outcomes. In the pre‑specified subgroup of 74 patients with TBI, 64% 
were alive and free of massive transfusion at 24 h compared to 46% in the CCT arm (OR 2.12, 95% CI 0.84–5.34).
Conclusion: There was no difference in overall outcomes between VHA‑ and CCT‑augmented‑major haemorrhage 
protocols.
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Introduction
Major haemorrhage after trauma is estimated to be 
responsible for nearly half of the annual 4.6 million injury 
deaths worldwide [1]. Up to 50% of critically bleeding 
patients will die, either early from exsanguination, or 
later from multiple organ dysfunction or associated trau-
matic brain injury [2, 3].
Current approaches to trauma resuscitation focus 
on control of bleeding and management of trauma-
induced coagulopathy with the timely administration 
of haemostatic therapy [2, 4]. In the initial phases of 
care, these therapies are often delivered empirically as 
part of a major haemorrhage protocol (MHP), deliver-
ing tranexamic acid, and blood components in propor-
tions that approach the composition of whole blood [5, 
6]. However, it is known that these strategies are rarely 
able to fully correct coagulopathy once established [7, 8], 
and all patients receive the same management approach, 
regardless of the severity or nature of their haemostatic 
deficits.
An alternative approach is a targeted and individual-
ized approach to diagnosing and correcting coagulopa-
thy. Conventional coagulation tests (CCTs) have been 
incorporated into algorithms but suffer from slow turn-
around times and may lack the ability to guiding indi-
vidual therapies [9]. We and others have investigated 
the diagnostic potential of point-of-care Viscoelastic 
Haemostatic Assays (VHAs) in trauma patients [9–15]. 
However, robust multi-centre and international rand-
omized trial data on the effectiveness of VHA-guided 
haemostatic therapy is lacking in trauma [16–20]. Our 
earlier work in over 2000 trauma patients developed 
trauma-specific algorithms [21], and we now wished to 
determine whether the application of a targeted strategy 
in addition to standard-of-care would improve outcomes 
after a major trauma haemorrhage.
The “Implementing Treatment Algorithms for the Cor-
rection of Trauma-Induced Coagulopathy (ITACTIC)” 
trial was designed to determine the efficacy of augment-
ing empiric standard MHPs with VHA-guided interven-
tions in improving outcomes from trauma haemorrhage, 
as compared to a standard MHP augmented by active 
CCT monitoring and guided interventions. We hypoth-
esized that VHA-augmented MHPs would improve mor-
tality and reduce the need for massive transfusion (ten or 
more units of red blood cell (RBC) transfusions) in the 
first 24 h after injury.
Methods
Trial design
The ITACTIC trial was a pragmatic, multi-centre, ran-
domized controlled trial involving injured patients who 
were suspected of having haemorrhage and who required 
at least one RBC transfusion. The trial compared out-
comes in patients who received an empiric MHP supple-
mented by haemostatic therapy guided by either CCTs 
(CCT group) or by VHAs (VHA group). The trial was 
registered at ClinicalTrials.gov (NCT02593877, Nov 1st, 
2015) and the protocol (Supplementary Materials) has 
previously been published [22].
Participating centres were members of the Interna-
tional Trauma Research Network (www.intrn .org) and 
were chosen on the basis of their ability to deliver the 
study design, expected enrolment rates, and the use of a 
standard empiric major haemorrhage protocol conform-
ing to relevant national guidance and including balanced 
blood component therapy and empiric use of tranexamic 
acid. The trial was conducted at seven major trauma cen-
tres in Europe (Rigshospitalet (Copenhagen, Denmark), 
Amsterdam University Medical Centre (Amsterdam, The 
Netherlands), Oslo University Hospital (Oslo, Norway), 
Kliniken der Stadt Köln gGmbH (Cologne, Germany), 
The Royal London Hospital (London, UK), John Radcliffe 
Hospital (Oxford, UK) and Nottingham University Hos-
pitals, Queens Medical Centre (Nottingham, UK)). The 
VHA device used at each study site (Thromboelastogra-
phy—TEG 6S Haemostasis Analyzer, Haemonetics® Cor-
poration, or Rotational Thromboelastometry—ROTEM® 
Sigma, TEM Innovations GmbH) was determined by 
existing familiarity with a specific device appliance and to 
ensure a balanced use of the devices across the study.
The trial was designed by the authors, and the design 
was approved by the trial sponsor (Queen Mary Univer-
sity of London) and the national research ethics commit-
tees of participating institutions. Clinical trial oversight, 
monitoring and data management were conducted by the 
clinical studies unit of the Centre for Trauma Sciences, 
Queen Mary University of London. An independent Data 
Monitoring Committee and a Trial Steering Committee 
provided oversight of trial activities.
Patient population
Adult trauma patients were enrolled if they presented 
with clinical signs of bleeding activating the local MHP 
and if RBC transfusion had been initiated. Participants 
had to be randomized within 3 h of injury and maximum 
Take‑home message 
When standard of care is delivered with empiric balanced hae‑
mostatic therapy and intensive conventional coagulation testing, 
viscoelastic haemostatic assays did not improve clinical outcomes in 
the intention to treat cohort.
of 1  h after admission to the emergency department. 
There were no additional exclusion criteria.
Consent for initial enrolment in the trial was provided 
on behalf of incapacitated patients by a nominated con-
sultee, usually an independent clinician in charge of 
patient care. Subsequent consent was given by a per-
sonal consultee (e.g. a family member) when identified 
and able to go through the informed consent process. 
Individual informed consent was subsequently obtained 
if the patient regained the physical and mental capacity 
to provide such consent. If the patient died or was other-
wise unable to give consent, previous nominated profes-
sional or personal consultee consent remained in effect. 
Patients who subsequently withdrew their consent were 
removed from the trial.
Randomization and blinding
Enrolled patients were randomized in a 1:1 ratio to the 
VHA or the CCT groups, with block randomization by 
the centre. Randomization codes were generated and 
secured by an independent statistician. Block size was 
unknown to on-site study teams. Group allocation was 
by study personnel opening the numbered opaque sealed 
envelope in sequence taken from a stack held by each 
study site. Once an envelope had been opened, the sub-
ject was considered enrolled. The trial was un-blinded to 
the treating clinical teams, while research personnel col-
lecting subsequent safety and outcome data were blinded 
to group allocation.
Procedures
All patients received their local hospital’s standard MHP, 
based on the empiric delivery of tranexamic acid; blood 
components delivered in a 1:1:1 ratio of RBCs, plasma 
and platelet transfusions; and limited infusion of crystal-
loid fluids. In both groups, blood was drawn for coagu-
lation analysis at baseline and after every four units of 
RBCs transfused, until haemostasis. In the CCT group, 
these were the conventional coagulation tests performed 
in the laboratory, while in the VHA assays, analyses were 
performed at the point of care. Haemostatic therapy was 
delivered based on results of these according to the TAC-
TIC algorithms [21], which define triggers for additional 
administration of platelet, fibrinogen, plasma and antifi-
brinolytic therapies.
Definitions
The time of haemostasis was defined as 1 h after the last 
RBC transfusion was given and the treating clinicians 
stated haemostasis had been achieved. Massive transfu-
sion was defined as the administration of ten or more 
units of RBCs in the first 24 h after injury. Severe trau-
matic brain injury (TBI) was defined as an Abbreviated 
Injury Scale score in the brain of four, five, or six [23]. 
We used an anatomical head injury score rather than an 
assessment of admission level of consciousness as the 
latter is affected by the depth of shock in this group of 
patients. We used prothrombin time ratio (PTr) as a test 
of coagulation available in both arms of the trial [24] and 
defined PTr > 1.2 as abnormal. For reporting blood com-
ponent therapy across study centres, one pool of cryo-
precipitate was considered equivalent to two grams of 
fibrinogen concentrates (or fibrinogen equivalent dose in 
grams); and platelet concentrates are reported as admin-
istered in pooled components (one pool = four individual 
platelet units).
Outcomes
The primary outcome of this study was the proportion 
of subjects who, at 24 h after injury, were alive and free 
of massive transfusion. Secondary endpoints included: 
all-cause mortality at 6  h, 24  h, 28  days, and 90  days 
post-admission; total blood components; 28-day venti-
lator-free, and intensive care unit (ICU)-free days; total 
hospital length-of-stay; and the proportion of patients 
with symptomatic thromboembolic events, with multiple 
organ dysfunction, and with serious adverse events.
Statistical analysis
The planned sample size for this study was 392, 196 in 
each study arm. Prior data from the study centres esti-
mated that approximately 28% of patients die or receive 
a massive transfusion by 24  h. Based on an estimated 
reduction in this proportion to 15% in the VHA group, 
and with a significance level of 0.05 using a two-sided 
test, 170 patients per group were required to achieve 80% 
power, increasing to 196 per group to account for a pre-
dicted drop-out rate of 15%.
All primary and secondary outcomes were analysed 
as intention-to-treat and per-protocol. The per-protocol 
group was defined excluding patients who did not have 
at least one VHA or CCT test performed, who did not 
meet the inclusion criteria, who received the wrong test, 
who died within 60  min after baseline blood sampling 
or who achieved haemostasis within 60  min of baseline 
sampling.
The primary endpoint was assessed by logistic regres-
sion to produce an odds ratio with 95% confidence inter-
val. Mortality was compared between the two arms as a 
binary outcome by logistic regression and using Kaplan–
Meier methods and the log-rank test. Time to haemo-
stasis, 28-day ventilator-free and ICU-free days, total 
hospital length-of-stay, EQ-5D quality-of-life scores, 
total number of blood products transfused, numbers 
receiving study intervention (post-hoc analysis) and time 
to intervention (post-hoc analysis) were compared using 
the Wilcoxon–Mann–Whitney or Chi-square tests. Miss-
ing data for the primary outcome were not expected. For 
secondary outcomes, data were assumed to be missing 
at random, therefore participants with missing data for a 
measure were excluded from any statistical comparisons 
regarding that measure. Denominators for analyses are 
presented throughout.
Pre-specified subgroups of interest were patients 
with and without severe TBI (defined as having an 
injury to the head of Abbreviated Injury Scale score of 
4 or more); patients with a prolonged PTr at baseline; 
patients receiving a massive transfusion; and patients on 
prior oral anticoagulant therapies. Stratification within 
subgroups was not possible as laboratory and imag-
ing results were not available at the time of randomiza-
tion and enrolment. The pre-defined subgroups were 
analysed by intention-to-treat for the primary outcome 
(except for the patients receiving a massive transfusion 
as not applicable) and some secondary outcomes (post-
hoc analyses), such as 28-day mortality, total number 
of blood products, numbers receiving study interven-
tion and time to intervention. As a comparison with 
the opposite subgroup, patients without a prolonged 
PTr were also analysed (post-hoc analysis). Interaction 
p-values were calculated (post-hoc analysis) to inspect 
the effect of each subgroup on the outcome of interest. 
The primary endpoint and 28-day mortality analyses 
for the severe TBI subgroup were also performed add-
ing covariates to the logistic regressions to adjust for any 
risk differences between study arms at baseline (post-hoc 
analysis). Statistical analyses were performed using Stata 
version 13. All applied tests were two-sided and p-values 
of less than 0.05 were considered statistically signifi-
cant. A pre-defined interim analysis was performed after 
the enrolment of 100 patients and the Data Monitoring 
Committee reviewed all data on outcomes for every 50 
patients enrolled. The statistical analyses plan is pre-
sented in the Supplementary Materials.
Results
From 1st of June 2016 to 30th of July 2018, 480 trauma 
patients were eligible for enrolment, of which 411 were 
randomized. 15 patients subsequently withdrew con-
sent, leaving 396 subjects for the intention-to-treat 
analysis (Fig. 1): 201 patients were allocated to the VHA 
group and 195 to the CCT group. Baseline character-
istics were well matched between treatment groups 
(Table  1). Two-thirds of the intention-to-treat cohort 
had sustained blunt trauma alone, and the overall 
median Injury Severity Score (ISS) was 26 (interquar-
tile range (IQR) 17–36, with a score over 15 indicat-
ing severe trauma). The median time from injury to 
admission was 69 min (IQR 45–96 min). At enrolment, 
participants had already received a median of two units 
of RBCs (IQR 1–4) and 9 had already received mas-
sive transfusion (ten or more units of RBCs). Of the 
377 patients who received tranexamic acid, 268 (71%) 
received the 1 g bolus prior to enrolment.
After enrolment and before haemostasis, 120/178 
(67%) patients in the VHA group received a study 
intervention, compared to 62/170 (36%) in the CCT 
group (Supplementary Table  S1). The study interven-
tions were given a median of 21 min earlier in the VHA 
group (VHA 61  min, IQR 48–85; CCT 80  min, IQR 
60–106, Supplementary Table  S1), with 89/139 (64%) 
of patients in the VHA group receiving the first study 
intervention within 3  h of injury compared to 45% 
(39/86) in the CCT group. Between baseline and hae-
mostasis, patients received a median of three units of 
RBCs and four units of plasma in both arms of the trial 
(Supplementary Table S1). Within this period, patients 
in the VHA arm received more fibrinogen supplemen-
tation (median fibrinogen equivalent dose—VHA: 4  g, 
IQR 0–4; CCT: 0 g, IQR 0–4 Supplementary Table S1).
At 24 h after injury, there was no difference between 
the two groups in the proportion of patients who were 
alive and free of massive transfusion (VHA 67%, CCT 
64%, OR 1.15, 95% CI 0.76–1.73, Fig.  2). In the VHA 
arm, 29/201 (14%) of patients had died and 53/201 
(26%) had received a massive transfusion at 24 h, while 
in the CCT arm, 33/195 (17%) of patients had died 
and 55/195 (28%) had received a massive transfusion 
(Table  2). At 28  days, 50/201 (25%) of patients in the 
VHA arm and 55/194 (28%) patients in the CCT arm 
had died (OR 0.84, 95% CI 0.54–1.31, Table 2 and Sup-
plementary Figure S1). This pattern persisted to 90 days 
(Fig. 3).
There were no statistically significant differences 
in other secondary outcomes between the two study 
groups, including the rate of multiple organ dysfunction, 
the incidence of symptomatic thromboembolic events, 
and a number of ventilator-free days or ICU-free days at 
day 28 (Table 2). Hospital length-of-stay was also similar 
in both groups and so were quality-of-life (EQ-5D) scores 
at both discharge/28  days and 90  days (Table  2). Safety 
and cause-of-death profiles were similar across the two 
groups (Table 3).
For the per-protocol analysis, 83 patients were 
excluded from the ITT cohort: five for not meeting the 
entry criteria, eight for receiving the wrong treatment, 
and 54 for reaching haemostasis and 16 for dying within 
the first hour (Fig.  1). This left 313 patients in the per-
protocol cohort (150 VHA, 163 CCT, Fig. 1). There was 
no statistically significant difference between study arms 
for the primary outcome or for 28-day mortality in the 
per-protocol group (Fig. 2 and Supplementary Fig. S1).
Across the pre-specified subgroups, there was no 
statistically significant difference in the primary out-
come (Fig.  2). In the subgroup of 74 patients who 
presented with severe TBI, 25/49 (64%) patients in 
the VHA arm were alive and free of massive trans-
fusion at 24  h, compared to 16/35 (46%) in the CCT 
arm (OR 2.12 95% CI 0.84–5.34). After risk adjust-
ment for admission characteristics, this odds ratio was 
unchanged at 2.10 (95% CI 0.51–8.61, Supplemental 
Table S3). Additional analyses on secondary outcomes 
of the TBI and other subgroups are presented in the 
Supplementary Materials (Fig. S1, Tables S1–S3).
Fig. 1 CONSORT diagram. CCT conventional coagulation test, VHA Viscoelastic Haemostatic Assay, TBI traumatic brain injury
Discussion
Our international randomized trial has evaluated the 
role of VHAs to individualize care and augment empiric 
haemostatic resuscitation in the challenging and time-
critical environment of trauma care. Empiric haemostatic 
therapy was delivered in both arms of the trial, with bal-
anced blood component transfusions, use of tranexamic 
acid and restricted crystalloid infusions. Intensive coagu-
lation monitoring was also performed in both arms after 
every four units of red cell transfusions, with additional 
haemostatic therapies delivered based on these results. 
We saw no difference overall in primary or secondary 
outcomes between CCT and VHA-guided haemostatic 
therapy.
While this study aimed to explore the effect of VHA-
directed assessment and treatment of coagulopathy in 
trauma patients, the overall prevalence of coagulopathy 
was lower than we expected. Nearly three quarters of 
the patients were not coagulopathic (by PTr) at base-
line and very few of these patients subsequently devel-
oped a prolonged PTr before haemostasis. These lower 
rates are likely due to the effect of optimisation of bal-
anced haemostatic therapy with early prehospital and 
in-hospital use of transfusions prior to randomisation 
and during haemorrhage. This alone was not sufficient 
to prevent trauma-induced coagulopathy, as coagula-
tion deficits identified by CCTs resulted in treatment 
in 36% of patients in this arm of the trial (Supplemen-
tary Table  S1). A previous single-centre trauma study 
reported a larger benefit with VHA-directed therapy, 
but subjects in the control arm received less empiric 
haemostatic transfusion therapy and the role of CCT 
monitoring during bleeding was not reported [25]. For 
those patients who never developed a coagulopathy, 
it is unsurprising that coagulation monitoring did not 
alter the clinical outcome. The relatively high numbers 
of these patients in our study reduced our ability to 
detect a difference in clinical outcomes.
Despite the delivery of optimized and individualised 
standard of care in both cohorts, 67% of patients in 
the VHA-augmented cohort received study interven-
tions, 1.8 times more than in the CCT group. This indi-
cates the widespread occurrence of coagulation deficits 
which were not detected by the CCTs. We are unable 
to ascertain in this analysis if these deficits were cor-
rected by the directed therapies or whether the doses 
prescribed within the algorithms were too low.
Table 1 Demographics, injuries and admission characteristics and initial therapies (intention‑to‑treat population)
CCT conventional coagulation test, VHA viscoelastic haemostatic assay, IQR interquartile range, TBI traumatic brain injury, AIS abbreviated injury scale, PTr prothrombin 
time ratio, RBC red blood cell, FFP fresh frozen plasma
^The other categorisations used for a type of trauma were: penetrating; or blunt and penetrating combined
CCT (n = 195) VHA (n = 201)
Median age (IQR) 43 (28–59),  n = 194 40 (26–54),  n = 197
Male sex – no. (%) 159/194 (82%) 145/198 (73%)
Prior oral anticoagulation – no. (%) 15/192 (8%) 12/198 (6%)
Injuries & Admission Physiology
Injury caused by blunt trauma alone^ – no. (%) 130/194 (67%) 133/198 (66%)
Median Injury Severity Score (IQR) 26 (16–35),  n = 191 26 (17–37),  n = 196
Severe TBI (AIS Head > 3) – no. (%) 35/191 (18%) 39/201 (20%)
Median time from injury to admission (IQR) – min 67 (42–98),  n = 191 70 (48–95),  n = 195
Median heart rate (IQR) – beats/min 105 (82–123),  n = 181 103 (87–127),  n = 190
Median systolic blood pressure (IQR) – mmHg 90 (74–110),  n = 170 95 (73–120),  n = 178
Median Glasgow Coma Scale score (IQR) 13 (3–15),  n = 191 12 (3–15),  n = 194
Patients with PTr > 1.2 – no. (%) 58/181 (32%) 44/175 (25%)
Median base deficit (IQR) – mEq/L 7.2 (4.2–13),  n = 188 8.2 (4.4–12.8),  n = 190
Median lactate (IQR) – mEq/L 4.4 (2.8–8.2),  n = 185 4.5 (2.9–8),  n = 191
Median fibrinogen level (IQR) – g/L 2.0 (1.4–2.4),  n =  n = 177 1.9 (1.5–2.4),  n = 166
Pre-baseline therapy
Received tranexamic acid bolus—no. (%) 190/193 (98%) 187/200 (94%)
Median units of RBCs (IQR) 2 (1–4),  n = 179 2 (1–4),  n =  n = 187
Median units of FFP/Octaplasma (IQR) 0 (0–2),  n = 179 0 (0–2),  n = 187
Median equivalent dose of fibrinogen (IQR) – g 0 (0–0),  n = 184 0 (0–0),  n = 185
Median units of Platelets (IQR) 0 (0–0),  n = 179 0 (0–0),  n =  n = 187
The reduction in 28-day mortality in the VHA group 
observed in patients who also had severe TBI was unex-
pected and may have been a chance finding. However, 
if borne out in future work, it potentially represents 
an important opportunity for improving outcomes in 
trauma care [26]. TBI is responsible for at least 25% 
of deaths in critically bleeding patients, and 50% of all 
trauma deaths [2]. Most previous clinical trials in trauma 
haemorrhage have excluded severe brain injuries as their 
outcomes were felt to be immutable by changes in hae-
mostatic management. There is a small but growing body 
of evidence that directed coagulopathy management may 
reduce brain injury mortality, such as the two recent tri-
als of tranexamic acid for TBI [27, 28]. Correction of 
coagulopathy may act to reduce intracerebral bleeding; 
decrease cerebral ischaemia due to reduced depth and 
duration of haemorrhagic shock; and/or reduce cerebral 
inflammation via crosstalk mechanisms, all of which con-
stitute important areas for future brain injury research. 
The ITACTIC results are consistent with these hypoth-
eses, and suggests this is an area for research in a field 
which has mostly focused on cerebral oxygenation and 
perfusion, and where there has been little change in prac-
tice or improvement in outcomes for some time [29–32].
This study was limited in a number of ways, including 
the lower observed difference in effect size in the primary 
endpoint between the two cohorts than originally pre-
dicted (observed: 3%, predicted: 13%). Empiric delivery 
of balanced transfusion and haemostatic therapies prior 
to randomisation and during haemorrhage likely contrib-
uted to this. Another caveat is that we did not adjust our 
secondary endpoint and post-hoc analyses for multiple 
comparisons due to the preponderance of non-significant 
results. As viscoelastic testing was only performed in 
the VHA group, we could not identify all coagulopathic 
patients and could not explore the effect of targeted ther-
apies in coagulation deficits that were only detectable by 
VHA. Interpretation of the results from our subgroups 
is also limited by lack of group allocation stratification, 
which was impossible with this study design, as neither 
coagulation status nor the presence of severe brain injury 
could be known prior to randomisation. The study was 
conducted at large major trauma centres, with experience 
of the use of VHA devices in a research setting, although 
most did not have VHA-guided care in routine clinical 
use at the start of the trial. The study was challenging to 
deliver on many levels and the experience in other cen-
tres may be different.
When standard care is delivered to bleeding trauma 
patients, with empiric balanced transfusion therapy 
and intensive CCT monitoring, VHAs identify more 
coagulation deficits and deliver additional haemostatic 
Fig. 2 Primary outcome (alive and free of massive transfusion at 24 h) in pre‑specified subgroups. Odds ratios for the primary outcome (alive and 
free of massive transfusion at 24 h) in the subgroups of coagulopathic patients at baseline (defined as PTr > 1.2), patients with severe TBI, patients 
with prior oral anticoagulants, the Per Protocol and Intention‑To‑Treat (Overall) populations. Odds ratios were calculated using the VHA arm as the 
exposed group. The solid black line indicates an odds ratio of 1, equivalent to no difference between study groups. The vertical red dashed line 
indicates the overall odds ratio for the ITT population. Subgroup allocation criteria were missing for some patients, so some subgroups do not add 
up to 396 patients. In particular, the following patients had missing data in their records: 40 did not have a PTr value at baseline, 9 did not have a 
TBI score, 6 did not have a record for prior oral anticoagulants. Post‑hoc analysis: the p‑values for the interaction between study arm and each sub‑
group were calculated using a logistic regression with “being alive and free of massive transfusion at 24 h” as the outcome. CI confidence interval, 
CCT conventional coagulation test, VHA viscoelastic haemostatic assay, PTr prothrombin time ratio, TBI traumatic brain injury, ITT intention‑to‑treat
Table 2 Secondary outcomes for the intention‑to‑treat population
Proportions were calculated excluding any missing records
CCT conventional coagulation test, VHA viscoelastic haemostatic assay, CI confidence interval, PTr prothrombin time ratio, TE thromboembolic events, MODS multiple 
organ dysfunction syndrome, ICU intensive care unit, LOS length of stay
^Patients with haemostasis (CCT: n =  n = 170, VHA: n = 178)
^^Myocardial infarction and Embolic strokes are included in thromboembolic events
^^^ Multiple Organ Dysfunction Syndrome (MODS) defined as having a Sequential Organ Failure Assessment score of 6 or more on a day
^^^^EQ-5D is a questionnaire by EuroQol used as a measure of overall health status
CCT (n = 195) VHA (n = 201) Odds ratio (95% CI) p value
Mortality at 6 h—no. (%) 22/195 (11%) 22/201 (11%) 0.97 (0.52–1.80) 0.915
Mortality at 24 h—no. (%) 33/195 (17%) 29/201 (14%) 0.83 (0.48–1.42) 0.495
Mortality at 28 days—no. (%) 55/194 (28%) 50/201 (25%) 0.84 (0.54–1.31) 0.435
Mortality at 90 days—no. (%) 56/177 (31%) 53/179 (29%) 0.91 (0.58–1.42) 0.678
Death from exsanguination—no. (%) 17/56 (30%) 13/51 (25%) 0.78 (0.34–1.82) 0.576
Died before haemostasis—no. (%) 24/54 (44%) 19/50 (38%) 0.77 (0.35–1.67) 0.505
Median time to haemostasis^ (IQR)—mins 122 (80–185),  n = 170 125 (77–185),  n = 176 0.929
PTr > 1.2 at haemostasis^—no. (%) 17/151 (11%) 21/142 (15%) 1.37 (0.70–2.69) 0.369
Massive transfusion at 24 h—no. (%) 55/195 (28%) 53/201 (26%) 0.91 (0.59–1.42) 0.682
Patients with symptomatic TE^^—no. (%) 27/195 (14%) 17/201 (9%) 0.57 (0.31–1.08) 0.088
Patients with MODS^^^—no. (%) 134/159 (84%) 141/164 (86%) 1.14 (0.62–2.10) 0.668
Median 28‑day ventilator‑free days (IQR) 20 (0–26),  n = 192 17 (0–25),  n = 198 0.422
Median 28‑day ICU‑free days (IQR) 15 (0–23),  n = 192 13 (0–23),  n = 198 0.691
Median hospital LOS in survivors (IQR) 24 (10–42),  n = 138 29 (13–49),  n = 147 0.147
Median EQ‑5D^^^^ index at discharge/28 days (IQR) 49 (25–60),  n = 86 40 (28–60),  n =  n = 92 0.672
Median EQ‑5D^^^^ index at 90 days (IQR) 60 (40–70),  n = 75 53 (40–70),  n = 72 0.718
Fig. 3 Survival curves at 24 h and 90 days. Survival curves with 95% confidence intervals at 24 h and 90 days for the Intention‑To‑Treat (ITT) popula‑
tion. Blue: CCT‑guided and Red: VHA‑guided. The p values shown are the result of the log‑rank test. 4 patients in the ITT population had missing 
date/time of events and were therefore not included in the survival curve. CCT conventional coagulation test, VHA viscoelastic haemostatic assay
interventions. However, all patients do not benefit from 
this approach and further research is required to iden-
tify injury types and physiologies that may benefit from 
this approach. Additional analyses should also explore 
the coagulation deficits identified by VHA alone, and 
the response of the coagulation system to the algo-
rithm-prescribed haemostatic agents.
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